Abstract: The invention relates to pharmaceutical powder compositions administered by means of inhalers. More particularly, it relates to pharmaceutical powder compositions having the content uniformity and the desired stability used in inhaler devices.

Abstract: Provided is a method for the synthesis of N-protected bis-3,6-[4-aminobutyl]-2,5-diketopiperazine including the step of heating a solution of ?-amino protected lysine in the presence of a catalyst selected from the group consisting of sulfuric acid, phosphoric acid, and phosphorus pentoxide.

Abstract: A microcapsule suspension for treating a protein-containing surface includes droplets of a dispersed water-immiscible core phase, an aqueous continuous phase, and a wall surrounding each core phase droplet. The wall includes the salt formed from at least one Lewis base reactant and at least one Lewis acid reactant, wherein at least one Lewis base reactant or Lewis acid reactant is amphiphilic and wherein at least one Lewis acid reactant is selected from the group consisting of proteins, protein hydrolysates, charged amino acids, and water-soluble salts of any of these.

Abstract: The present invention relates to the development of two types of polymer nanocapsules to encapsulate cloxacillin benzathine, an antimicrobial drug. More specifically, this invention relates to a new form of treatment for mastitis in dairy cattle. Two nanocapsule formulations have been developed and can be used to encapsulate various drugs, besides cloxacillin benzathine, providing a new therapy for mastitis in cows, avoiding the inconvenience of the use of high doses of drugs used in conventional formulations, thus contributing to an improvement in milk quality.

Abstract: Disclosed are conjugates of hydrophobic drugs linked to protected or unprotected amino acids or peptides. The disclosed conjugates are amphiphilic and can self assemble into nantubes. Nanotubes comprising the conjugates are also described and can have high loading of the drug and protect it from degradation or elimination. The nanotubes are well suited to deliver hydrophobic and unstable drugs to individuals.

Abstract: This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations.

Abstract: The invention relates to a pharmaceutical composition comprising a plurality of controlled-release coated microparticles each comprising a floating core, on the surface of which is deposited a layer containing at least one active principle, said layer being covered with a controlled-release coating, characterized by the fact that said floating core is composed of cellulose acetate phthalate and has an apparent density of less than or equal to 0.6 g/mL and said coated microparticles have a density of less than or equal to 0.7 g/mL.

Abstract: The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises inulin.

Abstract: Provided herein are methods for sequestering an alkyne-presenting molecule in a sample and related sequestration reagents, compositions, methods and systems.

Abstract: The present invention describes novel and improved dosage forms containing fluticasone propionate for the treatment of conditions associated with inflammation of the esophagus.

Abstract: The present invention is a technical filed of pharmaceutical preparation agent, and more particular to a pharmaceutical composition containing docetaxe. The pharmaceutical composition containing docetaxe includes docetaxel and a polyethylene glycol methyl ether-polylactide block copolymer with amino acid end groups. The advantage of the present invention is subjected to a tri-block copolymer with low toxicity as the drug carrier. In addition to the pharmaceutical active ingredients and carrier, there is no other additive in pharmaceutical composition containing docetaxe. Thus, the prescription is simpler and the security is higher. In pharmaceutical component containing docetaxel, docetaxel content is more than 20%, such that the preparation process of pharmaceutical component containing docetaxel is simple, and easy for the industrial applications.

Abstract: The present invention relates to a reducing or non-reducing polynucleotide polymer using a nucleotide from AMP, ADP, ATP, GMP, GDP, GTP, CMP, CDP and CTP, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), and N-hydroxy-succinimide (NHS) for drug delivery and a method for preparing same, and provides a reducing or non-reducing polymer synthesized by using nucleotides, a method for preparing same, and a polymer composition for drug delivery containing the reducing or non-reducing polymer.

Abstract: The present disclosure relates to a dermal drug delivery platform comprising: a primary wound dressing comprising three-dimensional polymer protuberances that extend upward from the dressing surface to engage the wound. The protuberances comprise at least one biocompatible and/or biodegradable polymer and medicinal nanoparticles. In one embodiment, the medicinal nanoparticles may be metallic and provide surface-area-enhanced galvanic action to drive medicinal ions into the wound bed. Various methods of making the disclosed dermal drug delivery platform, as well as three-dimensional methods of treating a wound using the platform are also disclosed.

Abstract: Magnetic drug-loaded polymeric particles are used in a transscleral drug delivery method. In the synthesis process of the aforementioned magnetic drug-loaded polymeric particles, therapeutic agents, along with a magnetic agent are encapsulated in a polymer. The aforementioned magnetic drug-loaded particles can be placed near the outer surface of the sclera, and then a magnetic field can be applied in front of the eye to pull these magnetic drug-loaded particles to the outer surface of the sclera, where these particles adhere to the outer surface of the sclera and thus, the orbital clearance of the particles is eliminated or reduced.

Abstract: Compositions are provided that provide release of fragrance over an extended period of time. The compositions comprise a hydrophilically-modified cross-linked silicone elastomer and an acrylic rheology modifier.

Abstract: The present invention generally relates to homogeneous suspensions of small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject in need thereof. The homogeneous suspensions may be used in combinations with various antigens or adjuvants for vaccine therapies.

Abstract: Described herein are polymeric nanoparticles that include a therapeutic agent which is 2-(3-((7-(3-(ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide (also known as AZD1152 hqpa) or a pharmaceutically acceptable salt thereof, and methods of making and using such therapeutic nanoparticles.

Abstract: The present invention provides targeted nanoplex molecules which carry multimodality imaging reporters together with target enzyme inhibitors such as siRNAs and target prodrug enzymes, that are useful for theranostic imaging of cells and diseases, including, for example, various cancers, and including metastatic prostate cancer. The nanoplex molecules of the present invention provide a platform technology toward many cancer subtypes and alternative therapeutic targets. Downregulation of specific pathways using targeted enzyme inhibitors further provides unique opportunities to target cancer cells selectively while sparing normal tissue. The nanoplex molecule platform described herein has the ability to deliver multiple siRNA enzyme inhibitors. Methods of diagnosis and treatment of various diseases are also included.

Abstract: The invention relates to a dry powder formulation comprising corticosteroid and a beta2-adrenergic drug in combination, its process preparation, and therapeutic uses thereof.

Abstract: Disclosed are formulations and related methods that comprise a non-polymeric, non-water soluble high viscosity liquid carrier material having a viscosity of at least 5,000 cP at 37° C. that does not crystallize neat under ambient or physiological conditions; a specified linear polymer comprising lactide repeat units; and one or more solvents that have a solvent capacity.

Abstract: This invention relates to new carbocyanine dye compositions, pharmaceutical compositions comprising such compositions, methods of detecting via near infrared fluorescent imaging incipient cancer cells and selective destruction of cancer cells identified by administration of such pharmaceutical compositions. A method of detecting and destroying cancer cells includes introducing a gold dye into an organism suspected of having a cancer cell. The gold dye is a carbocyanine dye covalently attached to a gold nanoparticle. A near infrared light is shined on a region suspected of having the cancer cell. Fluorescence from the gold dye is detected. A beam of radio frequency energy is directed at the region to induce hyperthermia in the cancer cell. The carbocyanine dye has the most basic structure of MHI-148 and structures 6 and 22 with a Aun—[CH2(CH2)9CH2—(OCH2CH2)4O]COCH2CH2-phenyl-O group on a cyclohexene ring that imparts activity to the cancer cell binding and destruction processes.

Abstract: Provided is a removable tattoo ink that is composed of colored micro-particles that create permanent tissue markings, such as tattoos. The micro-particles include an inner core housing a bio-absorbable chromophore and an outer shell, which includes polystyrene sulfonate and polyallylamine hydrochloride and is designed for rupture with ultrasonic energy. The micro-particles can be implanted in the tissue of a subject, for example to create a tattoo and ruptured in situ by the application of ultrasonic energy to remove the tattoo. Also provided are methods of making the colored micro-particles.

Abstract: The present invention provides, in part, a biodegradable compound of formula I, and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof, where each X independently is O or S, each Y independently is O or S, and each R1 independently is defined herein; and a liposome composition comprising the cationic lipid of formula I or a sub-formula thereof, and methods of delivering agents, such as nucleic acids including mRNA, in vivo, by administering to a subject the liposome comprising the cationic lipid of formula I or a sub-formula thereof, where the agent is encapsulated within the liposome.

Abstract: Nutritional supplement compositions that may provide sub-cellular phytonutrient delivery include a carrier oil base containing at least one triglyceride and also contain at least one biologically active complex in the carrier oil base. The biologically active complex may include a non-covalent complex of a carbon-60 fullerene, phytonutrient compound, and a triglyceride from the carrier oil base. The phytonutrient compound may be chosen from compounds having the ability to form non-covalent complexes with six-membered aromatic rings of carbon-60 fullerene. Examples of such phytonutrient compound include, for example, phenolic compounds, polyphenolic compounds, phenolic acids, flavonoids, terpenoids, tannins, stilbenes, curcuminoids, coumarins, lignans, quinones, phenylethanoids, carotenoids, astaxanthin, zeaxanthin, or coenzyme Q10. The nutritional supplement compositions may include multiple biologically active complexes in which the phytonutrient compounds are derived from olives, algae, or both.

Abstract: The present invention is directed to compositions comprising a polymer backbone with protective chain and anionic groups, and a cationic therapeutic agent. The present invention is directed to compositions for treating infections, inflammatory diseases, excess growth, and damaged cells and organs.

Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one carboxylate or carbamate ligand.

Abstract: Embodiments disclosed herein relates to ganglioside GM3-containing mixed lipids nanoparticles having an overall size between 60-100 nm, the making thereof and the uses. The nanoparticles selectively targeted to CD169+ expressing cells such as dendritic cells and macrophage. The nanoparticles are endocytosed by the CD169+ expressing cells.

Abstract: The invention relates to a method of preparation hydrophobized hyaluronic acid (Formula I) and further to a method of encapsulating biologically active substances into the nanomicelles of hydrophobized hyaluronan serving as carriers of biologically active hydrophobic substances. The hydrophobization of hyaluronan is carried out through an esterification reaction of hyaluronan with long-chain carboxylic acids, the latter being activated by a halogenide derivative of 2,4,6-trichlorobenzoic acid or by another organic chloride. In an aqueous environment, water-soluble hydrophobized derivatives can form nanomicelles in which nonpolar substances can be bound by means of non-covalent physical interactions. The core of a nanomicelle is formed by hydrophobic acyl functional groups while the shell of a nanomicelle is formed by hyaluronic acid. The encapsulation of the substances into nanomicelles can be performed by means of the solvent exchange method or by means of sonication.

Abstract: The present invention is related to novel functional antibody coated nanoparticles, and the preparation method thereof. The functional antibody coated nanoparticles according to the present invention can be used as photothermal agents to effectively inhibit the growth of microbes including drug-resistant strains and biofilm with laser irradiation.

Abstract: A therapeutic method for attenuating symptoms of inflammation and autoimmune diseases. This method includes preparing and administering to animals intraperitoneally or orally a metallic gold cluster complex preparation.

Abstract: Described herein are injectable corticosteroid-loaded microparticles, pharmaceutical composition thereof and methods for reducing inflammation or pain in a body compartment such as a joint, an epidural space, a vitreous body of an eye, a surgically created space, or a space adjacent to an implant.

Abstract: The present invention provides a process for preparing a particulate medicament that has greater homogeneity and a lower adhesion between the particles of the active ingredient and the carrier. The process comprises the steps of: (a) combining a pharmaceutically active ingredient in the form of an agglomerate of primary particles having an agglomerate particle size such that the agglomerate is capable of passing through a sieve having a mesh of 50-3000 .mu.m with a pharmaceutically acceptable particulate carrier, and (b) mixing the resultant material in a mixer to break up the agglomerate into primary particles dispersed in the pharmaceutically acceptable particulate carrier such that 90% or more of the pharmaceutically active ingredient exists as primary particles having a particle size of 50 .mu.m or less.

Abstract: Disclosed are nanoparticles comprising octapod iron oxide having eight trigonal bipyramidal arms and a method of preparing the same. The nanoparticles are prepared by heating a mixture of a ferric carboxylate, a carboxylic acid, a chloride salt, water, and a non-polar solvent, to a temperature above about 300° C. Also disclosed is a method of magnetic resonance imaging a tissue in a mammal, comprising use of the aforesaid nanoparticles.

Abstract: Compositions containing imidazole-based compounds, and optionally, colloidal oatmeal, for the treatment, prevention, and management of symptoms, conditions, diseases, and disorders of the skin. Also, methods for the treatment, prevention, and management of symptoms, conditions, diseases, and disorders of the skin using compositions containing imidazole-based compounds, and optionally, colloidal oatmeal.

Abstract: A dentinal tubule sealant including apatite particles (A) having an average particle diameter of 500 nm or less, a filler (B) having an average particle diameter of 1 to 10 ?m, and a dispersant (C), wherein the weight ratio (A/B) of the apatite particles (A) to the filler (B) is 0.05 to 15, the dentinal tubule sealant contains 15 to 95 parts by weight of the dispersant (C) relative to 100 parts by weight in total of the apatite particles (A) and the filler (B), and the total amount of the apatite particles (A), the filler (B), and the dispersant (C) is 85 parts by weight or more relative to 100 parts by weight of the dentinal tubule sealant. There is thereby provided a dentinal tubule sealant excelling in dentinal tubule sealability immediately after treatment, durability of dentinal tubule sealing, ease of operation, and storage stability.

Abstract: A modular energy application device for skin tissue treatment includes a first module, the first module including one or more skin treatment electrodes oriented on a surface to contact the skin tissue; a device to connect the first module to a source of electrical power and control; at least a second module, the second module including one or more treatment electrodes oriented on a surface to contact the skin tissue; a connection device to couple the first and the second modules; an electrical connection device to electrically couple the first and second electrodes; electrical power applied to the electrodes of the first module also applies electrical power to the electrodes of the second module.

Abstract: A process for reducing the particle size of an active pharmaceutical ingredient (API) while maintaining its polymorphic form, comprises the step of processing the active pharmaceutical ingredient by cavitation at elevated pressure. The process preferably comprises the step of isolating the processed active ingredient in the form of powder, wherein the isolation step comprises filtration or spray drying. Particles produced by the process of the invention typically have a span value of less than 2.5.

Abstract: The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.

Abstract: The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.

Abstract: A method for stabilising a human blood protein or human blood plasma protein with a molecular weight of >10 KDa by adding melezitose to a solution comprising the human blood protein or human blood plasma protein with a molecular weight of >10 KDa.

Abstract: A process for enabling the production of a particulate composition containing crystalline trehalose dihydrate is provided. Including allowing an ?-glycosyltrehalose-forming enzyme to act on liquefied starch derived from a microorganism of the genus Arthrobacter and a trehalose-releasing enzyme derived from a microorganism of the genus Arthrobacter along with a starch debranching enzyme and a cyclomaltodextrin glucanotransferase; allowing glucoamylase to act on the resulting mixture to obtain a saccharide solution containing ?,?-trehalose; precipitating crystalline ?,?-trehalose dihydrate from the above saccharide solution; collecting the precipitated crystalline ?,?-trehalose dihydrate by a centrifuge; and ageing and drying the collected crystals. Cyclomaltodextrin glucanotransferase derived from a microorganism of the genus Paenibacillus or a mutant enzyme thereof is used to increase the ?,?-trehalose content in the saccharide solution to over 86.

Abstract: Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition. The composition is highly stable at increased temperatures and relatively high humid environments, and are intended for storage at room temperature with an improved shelf-life. In particular, the dry powders are intended for inhalation, however, other routes of administration can be used when reconstituted in solution.

Abstract: An object of the present invention is to provide a water-solubilizing preparation that is obtained by convenient steps without use of a special apparatus such as a high-pressure homogenizer, does not impair the original properties of a water-based material even after being added to the material, has high dispersibility and transparency and excellent heat resistance and acid resistance, and can maintain stability. The water-solubilizing preparation of the present invention is a biologically active substance-containing water-solubilizing preparation comprising 1 to 50% by weight of an oily ingredient (A) containing a biologically active substance and oil, 10 to 98% by weight of a polyglycerin fatty acid ester (B) having an HLB value of 12.5 or larger, and 1 to 40% by weight of a surfactant (C) having an HLB value of 7 to 11.8.

Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions, into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g.

Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.

Abstract: A composition intended to be employed for therapeutic purposes incorporates an active ingredient (e.g., a source of nicotine) and at a non-active ingredient that is carried by a porous substrate. The non-active ingredient can be a substance that has the capability of affecting the pH of the biological system to which it is applied (e.g., basic substance and/or buffering agent is sorbed onto the porous carrier, so as to be in intimate contact with that carrier). Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) and nicotine polacrilex. The basic substance can be sodium carbonate, and the porous substrate can be microcrystalline cellulose. The composition is useful for treatment of central nervous system conditions, diseases, and disorders, and can be used as a nicotine replacement therapy.

Abstract: A method for increasing muscular volume of a muscle in a human is provided. The method comprises injecting a composition comprising hyaluronic acid (HA) into one or more than one location of a muscle, thereby increasing the muscular volume as compared to before the injection. The muscle may be an arm, leg, chest, back or buttock muscle, or any other desired muscle. A method for altering a contour of a muscle in a human is also provided, which comprises obtaining an image of the contour of the muscle, determining a new contour, injecting an HA composition into one or more than one location of the muscle to obtain the new contour, thereby altering the contour as compared to before the injection. A use of a composition comprising HA for increasing muscular volume of a muscle in a human is also provided, where the composition is for injection into muscle.

Abstract: Compositions having a plurality of hard particles and a plurality of lubricant nanoparticles are disclosed. Methods of making and using the compositions are also disclosed.

Abstract: The present invention relates to a solid cosmetic composition in the form of a powder, which is preferably compacted, comprising at least: —a pulverulent phase in an amount of greater than or equal to 35% by weight relative to the total weight of the composition, comprising at least one perlite in the form of particles in a content of greater than or equal to 20% by weight relative to the total weight of the composition, —a liquid fatty phase, and in which the perlite particles and the liquid fatty phase are present in the composition in a respective total content such that the weight ratio of the perlite particles to the liquid fatty phase ranges from 2 to 25. The present invention also relates to a process for coating the face, and in particular the cheeks, the chin, the temples, the forehead and the nose, with the said cosmetic composition.

Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in patient in need of such treatment.